Adagene Inc (ADAG) Actualités

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel...

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC

- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and...

Adagene to Participate in Investor Conferences in September

SAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with...